The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Prostate cancer ranks as one of the most diagnosed and challenging malignancies affecting
individuals worldwide. For hormone-dependent prostate cancer treatment Gonadotropin …

Two randomized controlled trials recently demonstrated an overall survival benefit with
triplet therapy (androgen receptor axis–targeted agent [ARAT]+ docetaxel+ androgen …

Background De novo oligometastatic prostate cancer (omPCa) on prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and …

Background Darolutamide is an androgen receptor pathway inhibitor (ARPI) used in patients
with prostate cancer (PC). In pivotal trials, it has demonstrated a favorable toxicity profile …

中国初诊的前列腺癌患者中40%~ 70% 已处于转移性疾病阶段, 而前列腺癌发生,
发展的时空异质性及独特的转移模式使得基于活检组织取材分析免疫标志物的方式困难重重 …

Background The nucleolus is considered the center of metabolic control and an important
organelle for the biogenesis of ribosomal RNA (rRNA). Nucleolar and coiled-body …

Multiple studies have demonstrated the importance of androgen receptor (AR) splice
variants (SVs) in the progression of prostate cancer to the castration-resistant phenotype …

Context The addition of androgen receptor signalling inhibitors (ARSIs) to standard
androgen deprivation therapy (ADT) has improved survival outcomes in patients with …

The androgen receptor (AR) is a crucial player in various aspects of male reproduction and
has been associated with the development and progression of prostate cancer (PCa) …